Your SlideShare is downloading. ×
0
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
UBS Global Life Sciences Conference
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

UBS Global Life Sciences Conference

1,032

Published on

Thursday, September 20, 2012 …

Thursday, September 20, 2012
9:00 AM E.D.T.

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,032
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
14
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. UBS 2012 Global HealthcareConferencePfizer WorldwideResearch & DevelopmentMikael Dolsten, M.D., Ph.D. September 20, 2012
  • 2. Forward-Looking Statements• Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2011 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.• Also, the discussions will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles. Reconciliations of those non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures can be found in Pfizer’s Current Reports on Form 8-K dated July 31, 2012 and August 13, 2012.These reports are available on our website at www.pfizer.comin the "Investors—SEC Filings" section. 2
  • 3. Pfizer R&D Strategy ― 3 Major Priorities Delivering the Innovating New R&D Ecosystem Portfolio Capabilities of the Future Sharpening focus in areas Investing in the Highly networked R&D with greatest scientific & technologies to enable & superior outcomes in commercial ROI tomorrow’s products Precision patient subsets • 8 Key Approvals • Antibody Drug • Centers for Therapeutic Conjugates Innovation (CTI) (2011 – 2012 YTD) • Therapeutic Vaccines • Xalkori • Eliquis and tofacitinib in Registration • Sophisticated NCE Design 3
  • 4. Improving R&D Return on InvestmentUnlocking Additional Value for Shareholders Three Key Principles 1 2 3 Greater Strategic Differentiated Focus Externalization Innovation Quality Probability Speed Cost of Output of Success • Termination of numerous non-core research projects • Neusentis (Pain) unit launched in Cambridge, UK • New portfolio prioritization & governance • CVMED & Neuroscience units moved to Cambridge, MA accountability • Acquired Icagen to expand Ion Channel research IP • Earlier integration of science, business & finance • Agreement with Mylan to acquire our A&R portfolio • Expanded Centers for Therapeutic Innovation • Acquired Excaliard Pharmaceuticals (CTI); agreements with 21 leading AMCs • Initiated Precision Medicine research collaboration • Transition from 17 functional service providers to 2 with Medco/Express Scripts strategic partners for clinical trials (ICON & Parexel) 4
  • 5. Today’s Key Late Stage Assets Key Post-POC Programs Key Products In Registration Eliquis™ (apixaban) Eliquis™ (apixiban) Venous Thromboembolism Treatment Stroke Prevention in AFib; US/EU/Japan Inlyta™ Tofacitinib First Line Renal Cell Carcinoma Rheumatoid Arthritis; US/EU/Japan Tofacitinib Tafamidis meglumine Psoriasis and Ulcerative Colitis Transthyretin amyloidosis polyneuropathy; US Dacomitinib (approved in EU) Non-Small Cell Lung Cancer Bosulif™ (bosutinib) Chronic Myelogenous Leukemia; EU Inotuzumab Ozogamicin (approved in US) Aggressive Non-Hodgkins Lymphoma and Acute Lymphoblastic Leukemia Remoxy™/ Embeda®* Pain; US Meningococcal B Adolescent Vaccine Prevention of Meningococcal Infection in Adolescents Xalkori® (crizotinib) ALK-positive Advanced NSCLC; EU PD-332991 (CDK 4/6) (approved in US and Japan) Advanced ER+HER2- Breast Cancer Bazedoxifene – conjugated estrogens *Planning re-submission of Embeda to relevant regulatory authorities Menopausal vasomotor symptoms, EU 5
  • 6. Precision Medicine R&D Shaping a Differentiated Pipeline Right Drug Right Target Right Patient (or Combinations) Selective design and Genetic validation; Rare Phenotyping and delivery; combinations phenotypes Genotyping for complex diseases PCSK9 Inotuzumab Nav family (targeted inhibition) PI3K/mTOR + Estrogen Inhibitors (in genetically-predisposed patients) PD-332991 (CDK 4/6) 6
  • 7. Coupled with Leading Technology PlatformsAcross Modalities Pfizer leads in cutting-edge …And is building technology platforms….. technologies of the future Vaccines Inflammation & Tissue-Specific Immunology NCEs CovX Bodies Peptides ADCs Oncology Neuroscience Targeted Antibody Mixtures IgG Heterodimers Vaccines NCEs Cardiovascular & Metabolic Disease Combinatorial Biologics Pain & Sensory Therapeutic DisordersAntibodies Proteins Biosimilars Long Lasting IgG Nexgen ADCs Rare Disease 7
  • 8. Next Wave Pipeline Shapes the Future Immunology & Inflammation Beyond RA: Transforming Chronic Disease IL6, MAdCAM P38, IL7R 8
  • 9. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Inflammation Metabolic Diseases Beyond RA: New Paths to Transforming Chronic Sustained Leadership Disease IL6, MAdCAM PCSK9, Gka P38, IL7R PDE5, FGF21 9
  • 10. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO 10
  • 11. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Platform for all Ages and Geographies Staph, Nicotine C. diff, IgE 11
  • 12. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Neuroscience & Pain Platform for all Ages Unlocking Circuitry and Geographies & Genetics Staph, Nicotine PDEs, Nav family C. diff, IgE 5HT6, AMPA 12
  • 13. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Neuroscience Biosimilars & Rare & Pain Diseases Platform for all Ages Unlocking Circuitry High-Value and Geographies & Genetics Specialized Markets Staph, Nicotine PDEs, Nav family Factor 7, rituximab C. diff, IgE 5HT6, AMPA trastuzumab, GDF8 13
  • 14. Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Neuroscience Biosimilars & Rare & Pain Diseases Platform for all Ages Unlocking Circuitry High-Value and Geographies & Genetics Specialized Markets Staph, Nicotine PDEs, Nav family Factor 7, rituximab C. diff, IgE 5HT6, AMPA trastuzumab, GDF8 14
  • 15. THANK YOU

×